NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
Clinical Trials
10 trialsNCT04521153 2025-05-11
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06796803 2025-02-10
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT02509806 2017-10-09
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
Hebei Medical University
Phase 2/3 Unknown
NCT02510469 2017-10-09
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University
Phase 2/3 Unknown
NCT03285906 2017-09-18
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02702323 2016-03-08
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Zhejiang Cancer Hospital
Phase 2/3 Unknown
NCT02409199 2015-11-18
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT00970138 2011-07-12
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2/3 Completed